InBody sells the scale for the Ozempic era and refuses to pick a favorite drugmaker

One scanner, every drugmaker

The obesity drug boom needs something it never budgeted for: a machine that can tell fat from muscle. InBody founder Cha Ki-chul has been selling such machines for 30 years ¹. In 1996 he visited one Wonju clinic about 20 times to close a single sale↗ ¹; now drugmakers approach him about cooperation, and he is holding off, because a tie-up with one would damage relationships with the others ¹.

The muscle the drugs burn

Semaglutide takes off about 15% of body weight on average, tirzepatide about 20%↗, and some of what goes is lean mass, which is why clinicians pair the drugs with protein targets and resistance training ⁴. A bathroom scale cannot tell fat from muscle; the machine that can is the opportunity.

The demand base keeps widening. Gallup puts GLP-1 weight-loss use at 11% of US adults in 2026, up from 3% in 2024↗, and the Korean analyst note lands on the same 11% ²⁵; the class took 14% of US drug spending last year ⁵. On InBody's own testimonial page↗, the weight-loss physician Dr. Adrienne Youdim says the scanner "made it possible for me to manage my clients at scale" ⁸.

Hospitals are now the engine

Korea Investment & Securities analyst Hong Ye-rim estimates InBody's US hospital sales rose more than 60% in the first half of 2026↗, after 28% growth last year, lifting hospitals from 37% to 44% of US revenue ². Machines sit in about 2% of roughly 224,000 US medical facilities ²³.

Margin tells the same story: the cost of building overseas direct sales squeezed operating margin from 26% down to 16%, and it recovered to 20% in Q2 2026, the first time in nine quarters ². The brokerage forecasts 288.1 billion won of revenue this year, up 23.1%, and 58.6 billion won of operating profit, up 59.4% ²; Cha expects 280 billion to 300 billion won of sales, and 500 billion within four or five years ¹.

One caveat: the 60% figure lives in a single analyst note; InBody has not disclosed hospital-sales growth itself.

The demand side has a leak

The boom feeding the scanner has a coverage problem. About 14% of US employers have dropped or plan to drop GLP-1 coverage in 2027↗, and the share of employers covering the drugs fell from 72% in 2025 to 60% in 2026 ⁶. Wegovy lists at $1,349 a month ⁶.

What no source here shows is the per-scan bill: whether insurers or patients pay for repeated scans, and how often, is not disclosed. InBody hedges the other way regardless: in July it became the official measurement partner of HYROX↗, the fitness-racing circuit, its old home turf ⁷.

The re-rating hangs on 2% and a signature

Two readings decide the re-rating: installed machines against that 2% penetration line, and whether Cha signs with any drugmaker at all. Hospitals already generate more than a third of sales and are the fastest-growing segment ¹. His 240 million accumulated measurements are worth most while every party still needs him ¹. "I don't think InBody has reached its peak yet" ¹.